Myeloproliferative Neoplasms
Mostrando 1-12 de 25 artigos, teses e dissertações.
-
1. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese
ABSTRACT Introduction: Constitutional symptoms and thrombohemorrhagic events are common in patients with myeloproliferative neoplasms (MPNs). Hence, the treatment’s primary goal is to control symptoms and improve the quality of life (QoL). In order to assess response to therapy, symptom burden, and QoL among patients with MPN, the “Myeloproliferative Ne
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
2. Erratum on "Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation"
ABSTRACT Introduction: von Willebrand's disease (VWD) is the most common inherited bleeding disorder. The 1-desamino-8-d-arginine vasopressin (DDAVP) is the treatment of choice for most responsive patients with VWD. The aim of this study was to evaluate DDAVP use in the management of VWD. Method: We implemented a survey targeting medical doctors involved i
Hematol., Transfus. Cell Ther.. Publicado em: 2021-03
-
3. Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic
ABSTRACT The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay.
Hematol., Transfus. Cell Ther.. Publicado em: 2020-09
-
4. Hott M. Luto: Trato & Retrato
ABSTRACT The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay.
Saúde debate. Publicado em: 2020-09
-
5. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
ABSTRACT Background: The classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). In developing countries, there are few reports that truly reveal the clinical setting of these patients. Therefore, we aimed to characterize a single center MPN population with a
Hematol., Transfus. Cell Ther.. Publicado em: 2020-09
-
6. Guideline on myeloproliferative neoplasms: Associação Brasileira de Hematologia, Hemoterapia e Terapia Cellular Project guidelines: Associação Médica Brasileira – 2019
Hematol., Transfus. Cell Ther.. Publicado em: 08/08/2019
-
7. Essential thrombocythemia - a predisponent factor for stroke
SUMMARY The essential thrombocythemia is one of the seven described forms of myeloproliferative neoplasms. It is characterized by megakaryocytic hyperplasia with consequent thrombocytosis maintained in the peripheral blood, favoring the occurrence of thrombo-hemorrhagic phenomena. We present the case of an 81-year-old woman with a history of ischemic stroke
Rev. Assoc. Med. Bras.. Publicado em: 22/07/2019
-
8. Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples
Cytogenetics is essential in myeloid neoplasms (MN) and pre-analytical variables are important for karyotyping. We assessed the relationship between pre-analytical variables (time from collection to sample processing, material type, sample cellularity, and diagnosis) and failures of karyotyping. Bone marrow (BM, n=352) and peripheral blood (PB, n=69) samples
Braz J Med Biol Res. Publicado em: 14/02/2019
-
9. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
ABSTRACT Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. Methods: This study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis,
Hematol., Transfus. Cell Ther.. Publicado em: 2018-06
-
10. Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms
Hematol., Transfus. Cell Ther.. Publicado em: 2018-06
-
11. l-Amino acid oxidase isolated from Calloselasma rhodostoma snake venom induces cytotoxicity and apoptosis in JAK2V617F-positive cell lines
ABSTRACT BACKGROUND: Myeloproliferative neoplasms are Philadelphia chromosome-negative diseases characterized by hyperproliferation of mature myeloid cells, associated or not with the Janus kinase 2 tyrosine kinase mutation, JAK2V617F. As there is no curative therapy, researchers have been investigating new drugs to treat myeloproliferative neoplasms, incl
Rev. Bras. Hematol. Hemoter.. Publicado em: 2016-06
-
12. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
ABSTRACTMyeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis in a subgr
Rev. Bras. Hematol. Hemoter.. Publicado em: 2015-10